For the year ending 2025-12-31, NDRA had -$2,467,115 decrease in cash & cash equivalents over the period. -$5,199,838 in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -7,027,410 |
| Depreciation and amortization | 44,045 |
| Stock compensation expense | 329,409 |
| Amortization of right of use assets | 113,249 |
| Fair value of vested advisory warrant | 665,030 |
| Digital asset staking compensation | 5,121 |
| Changes in fair value of warrant liability | -319,537 |
| Decrease/(increase) in prepaid expenses | 1,419 |
| Increase/(decrease) in accounts payable and accrued liabilities | 113,287 |
| Decrease in lease liability | -89,252 |
| Changes in fair value of digital assets | -995,161 |
| Fixed assets write off | 0 |
| Inventory reserve | 0 |
| Warrant expense | 0 |
| Gain or loss on settlement of warrant exercise | 0 |
| Decrease in inventory | 0 |
| Net cash used in operating activities | -5,182,558 |
| Purchases of fixed assets | 17,280 |
| Purchase of digital intangible assets | 3,000,000 |
| Proceeds from sale of fixed assets | 0 |
| Net cash used in investing activities | -3,017,280 |
| Proceeds from fundraising activities | 4,514,482 |
| Proceeds from issuance of common stock for cash | 1,218,241 |
| Proceeds from issuance of common stock for cashless warrant exercise - | 0 |
| Repayment of loan | 0 |
| Net cash provided by financing activities | 5,732,723 |
| Net increase (decrease) in cash | -2,467,115 |
| Net increase (decrease) in cash | -2,467,115 |
| Cash, beginning of period | 3,229,480 |
| Cash, end of period | 762,365 |
ENDRA Life Sciences Inc. (NDRA)
ENDRA Life Sciences Inc. (NDRA)